6533b855fe1ef96bd12b0060
RESEARCH PRODUCT
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
Jan Philipp BewersdorfVijaya Raj BhattDaniel J. DeangeloHuda S. SalmanAndre C. SchuhAaron D GoldbergPau MontesinosRaajit K. RampalJohn MascarenhasAref Al-kaliSelina M. LugerMartin S. TallmanMichael R. SavonaAmy E. DezernRami S. KomrokjiRoland B. WalterUwe PlatzbeckerDavid P. SteensmaFrancesco OnidaRory M. ShallisAmir T. FathiEric PadronHeiko KonigShyamala C. NavadaPrajwal C. BodduAlla KeyznerMichael W. DeiningerRichard StoneEunice S. WangBlanca Xicoy CiriciParesh VyasPierre FenauxMichal Bar-natanMikkael A. SekeresAmit VermaAmer M. ZeidanEytan M. SteinGabriela S. HobbsLewis R. SilvermanKeith W. PratzMaximilian StahlMrinal M. PatnaikJoshua F. ZeidnerValeria SantiniMarina KremyanskayaAndrew H. WeiGail J. RobozDavid T. BowenHarry P. ErbaElizabeth A. GriffithsAziz NazhaMark L. Heaneysubject
Adultmedicine.medical_specialtyMyeloidCoronavirus disease 2019 (COVID-19)Pneumonia ViralPopulationCovid 19 hematological neoplasia managementMEDLINEArticleResource AllocationBetacoronavirus03 medical and health sciences0302 clinical medicinePandemicHumansMedicineDisease management (health)Intensive care medicineeducationExpert TestimonyPandemicsInfection Controleducation.field_of_studyLeukemiaMyeloproliferative DisordersSARS-CoV-2business.industryPublic healthCOVID-19Disease ManagementHematology3. Good healthClinical trialmedicine.anatomical_structure030220 oncology & carcinogenesisPractice Guidelines as TopicCoronavirus Infectionsbusiness030215 immunologydescription
Summary The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be generalisable because of regional differences in health-care infrastructure, individual circumstances, and a complex and highly fluid health-care environment. Despite these limitations, we aim to provide a general framework for the care of patients with acute leukaemias and myeloid neoplasms during the COVID-19 pandemic on the basis of recommendations from international experts.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-08-01 |